1 BETA-CELL FAILURE IN DIABETES AND PRESERVATION BY ...
1 BETA-CELL FAILURE IN DIABETES AND PRESERVATION BY ...
1 BETA-CELL FAILURE IN DIABETES AND PRESERVATION BY ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
19<br />
217. Ahrén B 2004 Sensory nerves contribute to insulin secretion by glucagon-like<br />
peptide-1(GLP-1) in mice Am J Physiol Regul Integr Comp Physiol 286:R269-R272.<br />
218. Nauck MA,El-Ouaghlidi A 2005 The therapeutic actions of DPP-IV inhibition are<br />
not mediated by glucagon-like peptide-1 Diabetologia 48:608-611.<br />
219. Ahrén B,Simonsson E,Larsson H,Landin-Olsson M,Torgeirsson H,Jansson<br />
PA,Sandqvist M,Bavenholm P,Efendic S,Eriksson JW,Dickinson S,Holmes D<br />
2002 Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week<br />
study period in type 2 diabetes Diabetes Care 25:869-875.<br />
220. Ahrén B,Landin-Olsson M,Jansson PA,Svensson M,Holmes D,Schweizer A 2004<br />
Inhibition of dipeptidyl peptidase-4 reduces glycemia,sustains insulin levels ,and reduces<br />
glucagon levels in type 2 diabetes J Clin Endocrinol Metab 89:2078-2084.<br />
221. Holst JJ ,Deacon CF 2005 Glucagon-like peptide – 1 mediates the therapeutic<br />
actions of DPP-IV inhibitors Diabetologia 48:612-615.<br />
222. Drucker DJ 2006 DPP-4 inhibitors in the management of type 2 diabetes lide<br />
presentation). Mechanisms in Medicine Inc.,pag.59.<br />
223. Ahrén B 2000 Autonomic regulation of islet hormone secretion : implications for<br />
health and disease . Diabetologia 43:393-410.<br />
224. Filipsson K,Kvist Reimer M,Ahrén B 2001 The neuropeptide pituitary adenylate<br />
cyclase-activating polypeptide and islet function Diabetes 53:1959-1969.<br />
225. .Ahrén B ,Hughes TE 2005 Inhibition of DPP-IV augments insulin secretion in<br />
response to exogenously administered Glucagon-like peptide-1,Glucose-dependent<br />
insulinotropic polypeptide,Pituitary adenylate cyclase-activating polypeptide,and Gastrinreleasing<br />
peptide in mice. Endocrinology 146:2025-2029.<br />
226. Mest H-J ,Mentlein R 2005 Dipeptidyl peptidase inhibitors as new drugs for the<br />
treatment of type 2 diabetes Diabetologia 48:616-620.<br />
227. Mu J,Woods J,Zhou Y-P,Roy RS,Li Z,Zycband E,Feng Y,Zhu L,Li C,Howard<br />
AD,Moller DE,Thornberry NA,Zhang BB 2006 Chronic inhibition of Dipeptidyl<br />
peptidase –4 with a sitagliptin analog preserves pancreatic β--cell mass and function in a<br />
rodent model of type 2 diabetes Diabetes 55:1695-1704.<br />
228. Herman GA,Stevens C,Van Dyck K,Bergman A,Yi B,De Smet M,Snyder K,Hilliard<br />
D,Tanen M,Tanaka W,Wang AQ,Zeng W,Musson D,Winchell G,Davies MJ,Ramael<br />
S,Gottesdiener KM,Wagner JA 2005 Pharmacokinetics and pharmacodynamics of<br />
sitagliptin ,an inhibitor of dipeptidyl peptidase IV,in healthy subjects :results from tworandomized,double-blind,placebo-controlled<br />
studies with single oral doses. Clin Pharmacol<br />
Ther 78:675-688